[go: up one dir, main page]

ATE420191T1 - Promotoren zur expression im modifizierten vacciniavirus ankara - Google Patents

Promotoren zur expression im modifizierten vacciniavirus ankara

Info

Publication number
ATE420191T1
ATE420191T1 AT04790902T AT04790902T ATE420191T1 AT E420191 T1 ATE420191 T1 AT E420191T1 AT 04790902 T AT04790902 T AT 04790902T AT 04790902 T AT04790902 T AT 04790902T AT E420191 T1 ATE420191 T1 AT E420191T1
Authority
AT
Austria
Prior art keywords
expression
ankara
promotors
modified
vacciniavirus
Prior art date
Application number
AT04790902T
Other languages
English (en)
Inventor
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of ATE420191T1 publication Critical patent/ATE420191T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • A61K39/285Vaccinia virus or variola virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04790902T 2003-11-24 2004-10-27 Promotoren zur expression im modifizierten vacciniavirus ankara ATE420191T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24
EP04000943A EP1536015B1 (de) 2003-11-24 2004-01-17 Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Publications (1)

Publication Number Publication Date
ATE420191T1 true ATE420191T1 (de) 2009-01-15

Family

ID=34442836

Family Applications (4)

Application Number Title Priority Date Filing Date
AT04000943T ATE377088T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT07014231T ATE471383T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT08008470T ATE504654T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04790902T ATE420191T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression im modifizierten vacciniavirus ankara

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT04000943T ATE377088T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT07014231T ATE471383T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT08008470T ATE504654T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression in modifiziertem vaccinia virus ankara

Country Status (18)

Country Link
US (3) US7816508B2 (de)
EP (4) EP1536015B1 (de)
JP (2) JP2007512009A (de)
KR (1) KR20060109873A (de)
CN (1) CN1898390A (de)
AT (4) ATE377088T1 (de)
AU (1) AU2004295382A1 (de)
BR (1) BRPI0416916A (de)
CA (1) CA2546680A1 (de)
DE (4) DE602004009743T2 (de)
DK (3) DK1845164T3 (de)
EA (1) EA012846B1 (de)
IL (4) IL174653A0 (de)
NO (1) NO20062948L (de)
NZ (1) NZ547405A (de)
SG (2) SG169325A1 (de)
UA (1) UA90098C2 (de)
WO (1) WO2005054484A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3163902A (en) * 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
DE602004009743T2 (de) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
EP2042604A1 (de) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV-Promotergesteuerte Überexpression von rekombinanten Antigenen
NZ592082A (en) 2008-11-27 2013-03-28 Bavarian Nordic As Promoters for recombinant viral expression
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
EP2627774B1 (de) 2010-10-15 2018-11-21 Bavarian Nordic A/S Influenza impfstoff basierend auf einem rekombinanten modifizierten vaccinia ankara virus (mva)
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
EP3621646A4 (de) * 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center Mutanten des vaccinia-virus für die krebsimmuntherapie
WO2024193905A1 (en) 2023-03-17 2024-09-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
KR100880765B1 (ko) 2000-03-14 2009-02-02 버베리안 노딕 에이/에스 변형된 백시니아 바이러스 안카라(mva)의 변형 균주
AU3163902A (en) * 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
ES2334335T3 (es) * 2001-03-08 2010-03-09 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Mva que expresa genes de envoltura, gag y pol de vih modificados.
BR0310020A (pt) 2002-05-16 2005-02-15 Bavarian Nordic As Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
EP1529113B1 (de) * 2002-08-07 2011-04-06 Bavarian Nordic A/S Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
DE602004009743T2 (de) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Also Published As

Publication number Publication date
EP1689872A1 (de) 2006-08-16
CN1898390A (zh) 2007-01-17
EP1845164A3 (de) 2008-03-19
ATE377088T1 (de) 2007-11-15
CA2546680A1 (en) 2005-06-16
DK1536015T3 (da) 2008-02-18
EA012846B1 (ru) 2009-12-30
DK1689872T3 (da) 2009-04-27
UA90098C2 (en) 2010-04-12
ATE504654T1 (de) 2011-04-15
US7816508B2 (en) 2010-10-19
DE602004009743T2 (de) 2008-08-28
SG142300A1 (en) 2008-05-28
NZ547405A (en) 2008-06-30
IL199126A (en) 2010-12-30
EP1536015B1 (de) 2007-10-31
IL199128A (en) 2011-03-31
EP1845164A2 (de) 2007-10-17
US20110008792A1 (en) 2011-01-13
EP1689872B1 (de) 2009-01-07
US20110014242A1 (en) 2011-01-20
DE602004032187D1 (de) 2011-05-19
EA200601043A1 (ru) 2006-10-27
DK1845164T3 (da) 2010-09-20
EP1956094B1 (de) 2011-04-06
BRPI0416916A (pt) 2007-01-23
DE602004027767D1 (de) 2010-07-29
WO2005054484A1 (en) 2005-06-16
IL199127A (en) 2010-12-30
JP2011067219A (ja) 2011-04-07
EP1536015A1 (de) 2005-06-01
NO20062948L (no) 2006-08-23
DE602004009743D1 (de) 2007-12-13
ATE471383T1 (de) 2010-07-15
SG169325A1 (en) 2011-03-30
EP1845164B1 (de) 2010-06-16
IL174653A0 (en) 2006-08-20
JP2007512009A (ja) 2007-05-17
DE602004018975D1 (de) 2009-02-26
EP1956094A1 (de) 2008-08-13
KR20060109873A (ko) 2006-10-23
AU2004295382A1 (en) 2005-06-16
US20080112971A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
IL174653A0 (en) Promoters for expression in modified vaccinia virus ankara
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
NO20045480L (no) Intergeniske regioner som innskuddsseter i genomet til vacciniavirus ankara(MVA)
IL214460A0 (en) Malaria prime/boost vaccines
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
ATE532861T1 (de) Expressionsvektor
BR0310020A (pt) Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
BRPI0516576A (pt) vetores quiméricos
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
WO2005001096A8 (fr) Vaccins contre le sras
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase
WO2003091393A3 (en) Nucleic “acid molecules encoding human proteins, and uses thereof”

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1689872

Country of ref document: EP